Tetanus toxoid adsorbed vaccine

Hypersensitivity. Neurological disorder following a previous dose of vaccine.

Patient with bleeding disorders (including thrombocytopenia) or vitamin K deficiency, history of respiratory immaturity. Patient who developed Guillain-Barre syndrome within 6 weeks of receiving tetanus toxoid-containing vaccine. Defer immunisation in patients with acute infection or febrile illness; vaccination may be given in patients with mild acute illness (with or without fever). Consider delaying vaccination in patients with severe immunosuppression (e.g. receiving chemotherapy/radiation therapy or high-dose corticosteroids) until the end of the treatment; vaccination in patients with chronic immunosuppression (e.g. HIV infection) is recommended. Avoid vaccination more frequently than every 10 years in patients who have experienced Arthus-type hypersensitivity reaction following vaccination of tetanus toxoid. Patient receiving anticoagulant therapy. Very premature infants (born ≤28 weeks of gestation); infants and children (particularly if with neurological disease, history of febrile seizure, or cerebral damage). Pregnancy and lactation. Monitoring Parameters Monitor for hypersensitivity reaction and syncope for at least 15 minutes post-vaccination.

Significant: Anaphylactoid or hypersensitivity reactions (including Arthus-type hypersensitivity), syncope, Guillain-Barre syndrome, brachial neuritis. Blood and lymphatic system disorders: Lymphadenopathy, thrombocytopenia. Gastrointestinal disorders: Nausea. General disorders and administration site conditions: Inj site reactions (e.g. inflammation, warm sensation, pain, rash, induration, oedema; nodules which may develop into aseptic abscess), transient fever, malaise, irritability. Musculoskeletal and connective tissue disorders: Myalgia, arthralgia. Nervous system disorders: Dizziness, headache. Respiratory, thoracic and mediastinal disorders: Apnoea (particularly in very premature infants). Skin and subcutaneous tissue disorders: Urticaria, erythema nodosum, generalised pruritus, rash. Vascular disorders: Hypotension.

May decrease therapeutic effect with immunosuppressants. Risk of haematoma or bleeding following IM inj in patients receiving anticoagulant therapy.

Vaccines, Antisera & Immunologicals